(600165)"NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600165 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates significant losses, with total revenue and net profit both showing negative figures compared to the previous year. The company assures that the report's content is accurate and complete, taking legal responsibility for its disclosures.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Ningxia Zhongke Biotechnology Co., Ltd. on 6ix
Earlier from Ningxia Zhongke Biotechnology
- (600165)"NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD."Announcement on Departure of Independent Director
- (600165)"NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD."Announcement on Reaching the Halfway Stage of the Shareholding Increase Plan by the Actual Controller and Persons Acting in Concert and Progress of Shareholding Increase
- (600165)"NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD."Announcement on Reaching the Halfway Stage of the Shareholding Increase Plan by Certain Directors and Senior Executives and Progress of Shareholding Increase
- (600165)"NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD."Announcement on Resolutions of the 9th Meeting of the 10th Board of Directors
- (600165)"NINGXIA ZHONGKE BIOTECHNOLOGY CO., LTD."Announcement on Departure and Appointment of General Manager
Follow Ningxia Zhongke Biotechnology into a list and get an email when it puts out news.
Follow Ningxia Zhongke Biotechnology